Selecting oral bioavailability enhancing formulations during drug discovery and development
- 12 December 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 9 (2) , 139-150
Abstract
The role of chemical structure, lipophilicity, physico-chemical, absorption, distribution, metabolism, excretion, toxicity (ADMET) and biopharmaceutical properties of compounds including bioavailability are critical in drug discovery and drug dosage forms design. The authors discuss a number of parameters including computational approaches used for selected chemical structures with biological activity for lead optimization and chemogenomics and preclinical studies for ADMET process development of ligand properties. The authors also look at a number of other parameters including: early drug product formulations with method selection based on the biopharmaceutical classification system (BCS); in vitro-in vivo correlation (IVIVC) and different formulation strategies to enhance solubility; dissolution rate and permeability; bioavailability evaluation and quality by design as an opportunity to develop 'safe space' regions, where bioavailability is unaffected by pharmaceutical variations. The biopharmaceutical requirements for absorption are solubility and permeability. Both are influenced by lipophilicity, but in the opposite way. The genomic methodology, coupled with combinatorial chemistry, high-throughput screening, structure-based design and in silico ADMET would yield parameters as a starting point for the biopharmaceutical properties determination in further preclinical and clinical studies. Consecutive stages in drug discovery and development are irreplaceable, but pharmacokinetics is the critical step. Selection of drug formulations based on the BCS, IVIVC are the principal aspects to enhance the solubility and dissolution rate, while a rationale management of pharmaceutical and technological factors will enhance the bioavailability.Keywords
This publication has 68 references indexed in Scilit:
- How far can virtual screening take us in drug discovery?Expert Opinion on Drug Discovery, 2013
- The Role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System) in Drug DevelopmentJournal of Pharmaceutical Sciences, 2013
- BDDCS Applied to Over 900 DrugsThe AAPS Journal, 2011
- High-Throughput NIR-Chemometric Method for Meloxicam Assay from Powder Blends for TabletingScientia Pharmaceutica, 2011
- Pharmaceutical Cocrystals and Their Physicochemical PropertiesCrystal Growth & Design, 2009
- Clinical Relevance of Dissolution Testing in Quality by DesignThe AAPS Journal, 2008
- Use of the Biopharmaceutical Classification System in Early Drug DevelopmentThe AAPS Journal, 2008
- Chemogenomic approaches to rational drug designBritish Journal of Pharmacology, 2007
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profilingBritish Journal of Pharmacology, 2007
- The Many Roles of Computation in Drug DiscoveryScience, 2004